Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting
In patients with obesity or overweight, OW semaglutide 2.4 mg treatment was associated with decreased total medical HCRU and costs at 12 months.
Authors
- Wojciech Michalak (ORCID: https://orcid.org/0000-0002-3390-0182)
- Xin Zhao (ORCID: https://orcid.org/0000-0001-9798-7865)
- Prachi Arora (ORCID: https://orcid.org/0000-0002-7057-9033)
- Angela Fitch (ORCID: https://orcid.org/0000-0001-9912-5994)
- Bríain ó Hartaigh
- Zhenxiang Zhao
- Hong Yu (ORCID: https://orcid.org/0000-0001-5329-0492)
- Sara Álvarez (ORCID: https://orcid.org/0009-0002-6804-6470)
- Megan Fiasconaro
Institutions
- Know Center Research GmbH (Austria) (AT)
- Novo Nordisk (United States) (US)
- Novo Nordisk (United Kingdom) (GB)
- Genesis Medical Center (US)
- Genesis Research Institute (JP)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1080/14737167.2025.2570688
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00